Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/10165
Title: Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Authors: Menna-Barreto, Rubem Figueiredo Sadok
Belloze, Kele Teixeira
Perales, Jonas
Silva Jr., Floriano Paes
Affilliation: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica de Proteínas e Peptídeos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxinologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica de Proteínas e Peptídeos. Rio de Janeiro, RJ, Brasil.
Abstract: Chagas disease is endemic in Latin America and is caused by the protozoan hemoflagellate parasite Trypanosoma cruzi. Nowadays, it has also been disseminated to non-endemic countries due to the ease of global mobility. The nitroheterocycle benznidazole is currently used to treat this neglected tropical disease, although this drug causes severe side effects and has limited efficacy during the chronic phase of the disease. Proteomics and bioinformatics have recently become powerful tools in the identification of new drug targets. In the last decade, proteomic profiles of different T. cruzi forms under distinct experimental conditions were assessed. These reports have pointed to many potential drug targets, with ergosterol biosynthesis-related proteins and redox system enzymes being the most promising candidates. Nevertheless, the majority of the compounds active against T. cruzi still have unclear mechanisms of action, and most proteomic efforts have studied epimastigotes (the non-clinically relevant insect form of the parasite). Additional analyses with the clinically relevant parasite forms should be performed to identify proteins that actually bind drugs active against T. cruzi. Nonetheless, due to the known technical hurdles in generating such experimental data, bioinformatic approaches that integrate currently available data to generate additional knowledge will also be useful. Here, we review T. cruzi proteomics and describe the main chemoproteomic methods and their application to the identification of trypanosomatid drug targets. Finally, we discuss the potential benefits of more extensively integrating all proteomic data with other molecular databases via bioinformatic analyses to develop novel, viable strategies for alternative treatments of Chagas disease.
Keywords: Bioinformatics
Chagas Disease
Chemotherapy
Chemoproteomics
Drug targets
keywords: Doença de Chagas
Trypanosoma cruzi
Quimioterapia
DeCS: Quimioterapia
Doença de Chagas
Trypanosoma cruzi
Issue Date: 2014
Publisher: Bentham Science Publishers
Citation: MENNA-BARRETO, Rubem Figueiredo Sadok et al. Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle. Current Drug Targets, v.15, n.3, p.255-271, 2014.
DOI: 10.2174/13894501113146660218
ISSN: 1389-4501
Copyright: restricted access
Appears in Collections:IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
kele_bellozeetal_IOC_2014.pdf2.2 MBAdobe PDF    Request a copy


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.